MedTrace Logo

Pharmacokinetics and Safety in Healthy Volunteers

NCT03917628 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2021-01-29

No results posted yet for this study

Summary

Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.

Conditions

  • Healthy

Interventions

DRUG

SCT630

SCT630 single s.c. injection

DRUG

adalimumab-EU source

adalimumab-EU source single s.c. injection

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2019-11-04
Completion
2019-11-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917628 on ClinicalTrials.gov